Optimal medical treatment of hypertension in patients with coronary artery disease

References

• National Center for Health Statistics (US). Health, United States, 2015: With special feature on racial and ethnic health disparities. Report no.: 2016–1232.Hyattsville, MD: National Center for Health Statistics (US); 2016 May.
   Google Scholar
• World Health Organization (WHO). Causes of death 2008: data sources and methods. Geneva: Department of Health Statistics and Informatics, World Health Organization; 2011. 1–28.
   Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146–603.
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913.
   PubMed Web of Science ®Google Scholar
• Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health Nations Health. 1957;47:4–24.
   PubMedGoogle Scholar
• Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive And Lipid Lowering Treatment To Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9(4):342–360.
   PubMed Web of Science ®Google Scholar
• Dorresteijn JAN, van der Graaf Y, Spiering W, et al. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease. Hypertension. 2012;59:14–21.
   PubMed Web of Science ®Google Scholar
• Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562–2571.
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial- HOT study group. Lancet. 1998;351:1755–1762.
   PubMed Web of Science ®Google Scholar
• Elgendy IY, Bavry AA, Gong Y, et al. Long-term mortality in hypertensive patients with coronary artery disease. Hypertension. 2016;68(5):1110–1114.
   Web of Science ®Google Scholar
• Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144(12):884–893.
   PubMed Web of Science ®Google Scholar
• Protogerou AD, Safar ME, Iaria P, et al. Diastolic blood pressure and mortality in the elderly with cardiovascular disease. Hypertension. 2007;50(1):172–180.
   PubMed Web of Science ®Google Scholar
• Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction. BMJ. 1988;297(6658):1227–1230.
   PubMedGoogle Scholar
• Dorresteijn JAN, van der Graaf Y, Spiering W, et al. Secondary manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-Curve revisited. Hypertension. 2012;59(1):14–21.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–e248.
   PubMed Web of Science ®Google Scholar
• Rosendorff C, Lackland DT, Allison M, et al. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. Hypertension. 2015;65(6):1372–1407.
   PubMed Web of Science ®Google Scholar
• Wallace SM, McEniery CM, Mäki-Petäjä KM, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension. 2007;50(1):228–233.
   PubMed Web of Science ®Google Scholar
• Casadonte L, Verhoeff BJ, Piek JJ, et al. Influence of increased heart rate and aortic pressure on resting indices of functional coronary stenosis severity. Basic Res Cardiol. 2017;112(6):61.
   PubMed Web of Science ®Google Scholar
• Rouleau JR, Simard D, Blouin A, et al. Angiotensin inhibition and coronary autoregulation in a canine model of LV hypertrophy. Basic Res Cardiol. 2002;97(5):384–391.
   PubMed Web of Science ®Google Scholar
• Hoffman JI. Heterogeneity of myocardial blood flow. Basic Res Cardiol. 1995;90(2):103–111.
   PubMed Web of Science ®Google Scholar
• O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol. 2007;50(1):1–3.
   PubMed Web of Science ®Google Scholar
• Craven TE, Ryu JE, Espeland MA, et al. Evaluation of the associations between carotid artery atherosclerosis and coronary artery stenosis: a case-control study. Circulation. 1990;82(4):1230–1242.
   PubMed Web of Science ®Google Scholar
• Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290(7):898–904.
   PubMed Web of Science ®Google Scholar
• Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479–486.
   PubMed Web of Science ®Google Scholar
• Muntner P, Carey RM, Gidding S, et al. Potential US population impact of the 2017 ACC/AHA high blood pressure guideline. J Am Coll Cardiol. 2018;71(2):109–118.
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy. J Hypertens. 2012;30(11):2213–2222.
   PubMed Web of Science ®Google Scholar
• Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635.
   PubMed Web of Science ®Google Scholar
• Liu W, Mukku VK, Liu YY, et al. Long-term follow up of percutaneous coronary intervention of coronary artery disease in women ≤45 years of age. Am J Cardiol. 2013;112(7):918–922.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703–713.
   PubMed Web of Science ®Google Scholar
• Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435–443.
   PubMed Web of Science ®Google Scholar
• ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;2010(362):1575–1585.
   Google Scholar
• Margolis KL, O’Connor PJ, Morgan TM, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–1728.
   PubMed Web of Science ®Google Scholar
• SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;2015(373):2103–2116.
   Google Scholar
• Berlowitz DR, Foy CG, Kazis LE, et al. Effect of intensive blood-pressure treatment on patient-reported outcomes. N Engl J Med. 2017;377(8):733–744.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: the VALUE trial. Blood Press. 2016;25(2):83–92.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290(21):2805–2816.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Gong Y, Cooper-DeHoff RM, et al. 2014 Eighth Joint National Committee panel recommendation for blood pressure targets revisited: results from the INVEST study. J Am Coll Cardiol. 2014;64(8):784–793.
   PubMed Web of Science ®Google Scholar
• Gupta A, Mackay J, Whitehouse A, et al. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) legacy study: 16-year follow-up results of a randomised factorial trial. Lancet. 2018 Aug 24:pii: S0140-6736(18)31776–8 Epub ahead of print. DOI:10.1016/S0140-6736(18)31776-8.
   Web of Science ®Google Scholar
• McEvoy JW, Chen Y, Rawlings A, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68(16):1713–1722.
   PubMed Web of Science ®Google Scholar
• Wokhlu A, Smith SM, Gong Y, et al. Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease: long-term mortality results from the International Verapamil-Trandolapril Study US cohort. J Hypertens. 2018;36(2):419–427.
   PubMed Web of Science ®Google Scholar
• Vidal-Petiot E, Ford I, Greenlaw N, et al. CLARIFY investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142–2152.
   PubMed Web of Science ®Google Scholar
• Selvaraj S, Steg PG, Elbez Y, et al. REACH registry investigators. Pulse pressure and risk for cardiovascular events in patients with atherothrombosis: from the REACH registry. J Am Coll Cardiol. 2016;67(4):392–403.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Messerli FH, Franklin SS, et al. Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an International Verapamil Sr-Trandolapril Study (INVEST) analysis. Eur Heart J. 2009;30(11):1395–1401.
   PubMed Web of Science ®Google Scholar
• Morgan TO, Anderson AI, MacInnis RJ. ACE inhibitors, beta-blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens. 2001;14(3):241–247.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? JAMA. 1998;279:1903–1907.
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995–1003.
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Bradley HA, Volmink J, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2012;11:CD002003.
   Google Scholar
• Casey DP, Curry TB, Joyner MJ, et al. Acute β-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes. Hypertension. 2012;59(1):145–150.
   PubMed Web of Science ®Google Scholar
• Peart S, Greenberg G. MRC trial of treatment of mild hypertension. BMJ. 1985;291(6491):347.
   PubMedGoogle Scholar
• ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive And Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–2997.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. New Engl J Med. 1992;327(10):669–677.
   PubMed Web of Science ®Google Scholar
• European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782–788.
   PubMed Web of Science ®Google Scholar
• Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;2000(342):154–160.
   Google Scholar
• PEACE Trial Investigators. Angiotensin-converting–enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;2004(351):2058–2068.
   Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893–1906.
   PubMed Web of Science ®Google Scholar
• Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–553.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031.
   PubMed Web of Science ®Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2013;22(4):193–278.
   PubMed Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC scientific document group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Lund-Johansen P, Nilsson PM, et al. Unattended blood pressure measurements in the Systolic Blood Pressure Intervention Trial. Hypertension. 2016;67(5):808–812.
   PubMed Web of Science ®Google Scholar
• Wright JS, Wall HK, Ritchey MD, et al. Million Hearts 2022: small steps are needed for cardiovascular disease prevention. JAMA. 2018 Sep 6. Epub ahead of print. DOI:10.1001/jama.2018.13326
   PubMedGoogle Scholar